Plain-English translation of NCT07451912 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether venetoclax — a newer cancer medication — combined with two other drugs (hypomethylating agents and low-dose cytarabine) can effectively treat a specific type of blood cancer called acute myeloid leukemia (AML) in patients who cannot tolerate standard intensive chemotherapy. The study will measure how well this treatment combination works, how many patients go into remission, and what side effects occur.
Standard chemotherapy for blood cancer is too intense for some patients, especially older adults or those with other health conditions. This trial is exploring whether this medication combination can be gentler while still being effective for patients with this specific genetic type of blood cancer.
You likely qualify if…
You likely don't qualify if…
You will take three medications together in two phases. In the first phase (induction), you'll receive 2 cycles of 28-day treatment: venetoclax as a daily pill that starts at 100 mg and increases to 400 mg, plus two injected medications (either azacitidine or decitabine, and cytarabine). If your cancer responds well, you'll move to a second phase (consolidation) and receive at least 4 more cycles of the same treatment. Throughout treatment, you'll have regular check-ups including blood tests, bone marrow tests, and heart monitoring. After treatment ends, you'll be followed for 2 years to monitor your health and watch for any return of disease.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China